Covid-19 in Lupus Patients

Study Overview
=================
Brief Summary
-----------------
The Covid-19 pandemic is a major public health issue. Potential treatments are essential to control the infection. Hydroxychlorquine is currently tested in several clinical trials to evaluate its efficiency.The objective of this study was to evaluate the symptoms related to COVID-19 occuring in patients with systemic lupus erythematosus (SLE)

Detailed Description
-----------------
Introduction:The Covid-19 pandemic has had a major impact on many countries on the sanitary and economic level. Finding an efficient cure is paramount in order to reduce its severity and mortality. Several medications are currently under investigation. Among them, hydroxychloroquine can prevent viral replication at several sites and has been shown efficient in vitro. Several clinical trials are in progress to evaluate its efficiency in vivo. However, no study so far has evaluated the covid-19 infection in patients with SLE. Objectives and methods: The primary objective was to describe the prevalence and the severity of Covid-19 infection in patients wih systemic lupus erythematosus. The secondary objective was to compare these parameters in patients treated by hydroxychloroquine and those not treated by hydroxychloroquine. This observational study of a historical-prospective cohort focuses on all adult lupus patients seen during the last year in the departments of rheumatology and nephrology in CHU Montpellier. It will collect information concerning the patient's condition, treatments and main comorbidities (cardio-vascular, respiratory, hepatic and immune depression), as well as symptoms suggesting covid-19 infection, its confirmation and its course and severity.

Official Title
-----------------
Manifestations Related to Covid-19 in Patients With Systemic Lupus Erythematosus

Conditions
-----------------
Systemic Lupus Erythematosus, Covid-19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: - adult patient with systemic lupus erythematosus seen during the last year in the departments of rheumatology or nephrology Exclusion criteria: - patient not speaking french nor english

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Lupus patients treated by hydroxychloroquine<br>Lupus patients treated by hydroxychloroquine | |
| Lupus patients not treated by hydroxychloroquine<br>Lupus patients not treated by hydroxychloroquine | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prevalence and severity of Covid-19 infection in patients with SLE | prevalence and severity of Covid-19 infection in patients with SLE | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prevalence and severity of Covid-19 infection in patients treated by hydroxychloroquine | prevalence and severity of Covid-19 infection in patients treated by hydroxychloroquine | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Systemic lupus erythematosus, Hydroxychloroquine